ADT1186-Durvalumab Biosimilar-Anti-PD-L1 mAb-Research Grade

Catalog Number

ADT1186

Product Name

ADT1186-Durvalumab Biosimilar-Anti-PD-L1 mAb-Research Grade

Alias

MEDI4736

Isotype

IgG1 Kappa

Clonity

Monoclonal

Alternate Names

pd-l1 antibody, human pd-l1 antibody, mouse pd-l1, human cd274, recombinant cd274, anti-CD274, CD274 antibody, anti-CD274 antibody, anti-CD274 monoclonal antibody, anti CD274 antibody, mouse CD274, CD274 recombinant antibody, CD274 blocking antibody, pdl1 recombinant antibody, pd-l1 blocking antibody

Official Symbol

CD274/B7-H1/PDL1

Species

Human

Expression Host

CHO Cells

Reactivity

Human

Gene ID

29126

CAS Number

1428935-60-7

Chemical Formula

C6502H10018N1742O2024S42

Molecular Weight

146.3KDa

Product Description

Durvalumab (trade name Imfinzi) is an FDA-approved immunotherapy for cancer, developed by Medimmune/AstraZeneca. It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1) with the PD-1 (CD279). Durvalumab is known as a checkpoint Inhibitionitor drug.

Mechanism of Action

Because cancer cells express antigens that are recognized and taken up by antigen-presenting cells (APCs), the immune responses prime and activate cytotoxic T cells, and allow them to travel to the site of tumour to destroy cancer cells. However, tumours often evade T cell-mediated immune responses to enhance their survival. Inflammatory mediators, such as IFN-gamma, induce the expression of programmed cell death ligand-1 (PD-L1), which is a type 1 transmembrane protein expressed on tumour cells and tumour-associated immune cells in the tumour microenvironment. PD-L1 acts as an immune checkpoint to regulate immune responses. PD-L1 is a ligand to PD-1, which is a cell surface receptor expressed on activated T cells in peripheral tissues following antigen exposure. Both PD-L1 and PD-1 are co-Inhibitionitory molecules involved in blocking T cell-mediated immune responses. PD-L1 also interacts with CD-80, which is a receptor constitutively expressed by T cells and is upregulated early after T cell activation.

Metabolism

Durvalumab is subject to protein catabolism via reticuloedothelial system or target-mediated disposition.

Size

1mg,5mg

Research Area

Cancer

Application

ELISA, IHC, FC, IP, IF, Inhibition, Functional assay

Purity

>95% as determined by SDS-PAGE

Concentration

Batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only. 

Reference